Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ICOMES 2021 September 3-5

Semaglutide Significantly Reduced Abdominal Visceral Fat Area in Japanese Adults with Overweight or Obesity in the STEP 6 Trial

Soo Lim1; Joakim Isendahl2; Kristian Kandler2; Sang Yeoup Lee3,4; Tomoyuki Nishida5; Wataru Ogawa6; Kazuyuki Tobe7; Toshimasa Yamauchi8; Takashi Kadowaki9;
1 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea; 2 Novo Nordisk A/S, Søborg, Denmark; 3 Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea; 4 Department of Medical Education, Pusan National University School of Medicine, Yangsan, Korea; 5 Novo Nordisk Pharma Ltd., Tokyo, Japan; 6 Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; 7 First Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, Toyama, Japan 8 Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 9 Toranomon Hospital, Tokyo, Japan;